Tear trough filler can do one thing well: replace the lost volume beneath the orbital rim that casts a shadow and makes people look tired. When the right patient gets the right technique, results look natural and last. But the tear trough sits at the intersection of aesthetics and ophthalmology, and the gap between a good outcome and a serious one is anatomically narrow. Complications here range from a temporary blue tint that dissolves with enzyme to permanent vision loss. Every person considering this procedure deserves a clear account of the full spectrum - including the rare scenarios that most pre-treatment conversations skip entirely.
Why the Tear Trough Is the Hardest Place on the Face to Inject Safely
Three anatomical facts combine to make this region uniquely unforgiving.
The lower eyelid skin is approximately 0.5 mm thick - the thinnest skin on the human body. Cheek skin generally runs 1.5 to 2 mm depending on the facial region and measurement method. This matters practically: filler placed even slightly too close to the surface becomes visible under the eye as a lump or a bluish tint, while the identical mistake on the cheek stays hidden under several times as much overlying tissue.
The vascular anatomy is the second problem. The angular artery - a branch that connects ultimately to the ophthalmic artery, the primary blood supply to the entire orbit - runs superficially in the medial tear trough, lying above the orbicularis oculi muscle rather than deep to it in the majority of patients. Most facial arteries track along bone; this one does not. Its proximity to the surface means a needle entering the medial tear trough can reach it without any tactile warning.
The safest injection plane sits deep to the orbicularis oculi muscle and just above the maxillary periosteum - the sub-orbicularis oculi fat or periosteal plane. Staying there reduces arterial risk but does not eliminate it, because anatomy varies between patients and no injector can see where the needle tip is at the moment of delivery.
Limited tissue tension is the third factor. The lower lid has less structural support than most facial areas, which makes misplaced filler harder to hold in position and more likely to migrate over time - a problem discussed in full below.
Normal Post-Injection Effects vs. Early Warning Signs
Some swelling, bruising, and minor asymmetry after tear trough injection are expected. The challenge for patients is separating what is normal from what needs attention.
Normal in the first 48 to 72 hours:
- Mild puffiness at the injection site that begins to reduce by day three
- Purple or red bruising that shifts progressively to brown, then yellow, and fades within 7 to 14 days
- Slight difference between the two sides that resolves as swelling settles
- Tenderness to touch at the injection points
Signs that warrant same-day contact with your injector:
- Swelling that worsens after day three rather than declining
- A blue-gray tint that does not change color or fade the way bruising does
- A lump or ridge that hardens or becomes more obvious after the first week
- Skin blanching - white or pale patches near the injection site - or skin that darkens rapidly after injection
- Pain that intensifies rather than resolving
| Complication | Typical onset | Resolves without treatment? | Response needed |
|---|---|---|---|
| Bruising | Hours to days | Yes, within 2 weeks | Watch and wait |
| Tyndall effect | Days to weeks | No | Book a follow-up |
| Overfill / progressive puffiness | Days, worsening over time | No | Call injector promptly |
| Migration / caterpillar bag | Months to years | No | Elective review appointment |
| Delayed nodule | Weeks to years post-injection | Minor ones sometimes | Depends on severity |
| Vascular occlusion | During or immediately after injection | No | 999 / 911 emergency |
The Tyndall Effect: Not Bruising, and Not Temporary
When HA filler is placed too superficially - in the thin eyelid dermis rather than the deeper tissue plane - it scatters short wavelengths of visible light outward, producing a blue-gray discoloration at the surface. This is the Tyndall effect, a well-established physics phenomenon. Patients consistently mistake it for bruising.
The behavioral difference between the two is the diagnostic key. Bruising follows a predictable trajectory: purple shifts to brown, then yellow-green, then normal skin, typically within two weeks. The Tyndall effect does not change color. It does not fade progressively. It does not resolve on its own. A tint that is the same flat blue-gray at four weeks as it was at four days is not a bruise.
Treatment is hyaluronidase injected into the discolored zone. Because the superficially placed filler is close to the surface, the enzyme reaches it efficiently - most patients see clear improvement within 24 to 48 hours. The Tyndall effect is a technique problem, but it can happen even with experienced injectors, because the tissue plane in some patients' eyelids sits shallower than anatomy textbooks suggest.
Overfilling, Progressive Puffiness, and Migration
Why the puffiness worsens after you leave the clinic
Hyaluronic acid filler is hydrophilic: it attracts and binds water from surrounding tissue. At the moment of injection the volume is the volume of filler placed. In the days that follow, water absorption continues, increasing total volume beyond what was injected. Under the eye, where tissue tension is low and the skin reveals everything, even a small additional increase becomes visible.
Overfill-driven puffiness differs from normal post-injection swelling in trajectory. Normal swelling peaks within 48 hours and declines. Overfill-related puffiness either plateaus at an unacceptable level or continues worsening after that point. It does not resolve without hyaluronidase treatment.
Migration and the caterpillar bag
The lower eyelid's limited tissue tension makes filler migration more likely here than in the cheeks or lips. Migration - displacement of the product away from the original site - can appear months or years after a treatment that initially looked correct. The classic presentation is a rolled or elongated lump at the lid-cheek junction, sometimes called a 'caterpillar bag' because of its segmented appearance along the lower lid.
It may cause no discomfort and can go unnoticed until it appears in a photograph. Treatment is hyaluronidase. Filler that has been present for a long time can be more resistant to dissolution because cross-links in the HA product stiffen with age, and staged treatment may be needed.
Delayed Nodules: Why Stable Filler Can Flare After Illness or Vaccination
A systematic review of delayed tear trough filler complications found that lumps and nodules accounted for roughly a quarter of delayed adverse events - second only to delayed swelling in frequency. What the statistics do not capture is how disorienting this complication is for patients, because many of these nodules arrive long after the injection and are triggered by something with no apparent connection to it.
The mechanism is immune activation. When the body responds to a viral infection or a vaccination, it releases inflammatory signals systemically. In patients who have HA filler in periorbital tissue, those signals can reach the filler deposit and cause previously stable, undetectable product to swell, harden, or form a granuloma. The filler has not moved and was not causing any problem before the illness.
Patients in this situation are typically baffled: their filler was invisible for eight months, then they had a respiratory infection and woke up with a lump under one eye. Without knowing this connection is documented and recognized, many assume something went wrong with the injection retroactively.
Mild inflammatory nodules sometimes respond to oral anti-inflammatory medication or a local steroid injection. Persistent, enlarging, or painful nodules generally require hyaluronidase to remove the filler entirely. Granulomas need more extended management.
Vascular Occlusion and Vision Loss: The Emergency Scenario
How filler reaches the eye's blood supply
The angular artery in the medial tear trough connects upstream to the ophthalmic artery, which supplies the entire orbit. If filler enters this artery - either through direct accidental injection into the vessel, or through retrograde pressure that pushes material backward against normal blood flow - it can travel toward the eye. A filler particle that reaches the central retinal artery or the ophthalmic artery can block blood flow to the retina.
The retina is among the most ischemia-sensitive tissue in the body. Research indicates it can tolerate as little as 12 to 15 minutes of complete blood flow interruption before cells die irreversibly - some studies extend this to 90 minutes for partial occlusion - but no window offers genuine reassurance, because no currently available treatment reliably restores vision once retinal infarction has occurred.
A literature review of filler-related visual loss identified 233 published cases; 172 patients sustained severe visual impairment in at least one eye. Earlier systematic reviews tracking reported outcomes found complete visual recovery in only around 2% of cases; more recent analyses suggest the recovery rate may be slowly improving as reversible hyaluronic acid fillers have become more common, but published reviews consistently describe a poor overall prognosis. The estimated rate of vascular occlusion in the periocular region is approximately 1 in 1,000,000 injections - rare, but not theoretical, and catastrophic when it occurs.
Recognizing the emergency and what to do
Visual symptoms can begin during the injection or within minutes afterward. The steps below are a genuine sequence - order matters:
- If any visual change occurs during the procedure, stop the injection immediately.
- Call 999 or 911 and state clearly that you may have a filler-related vascular occlusion with visual symptoms.
- Do not drive. Do not call the clinic and wait for a callback. Do not take a painkiller and monitor overnight. Hospital-level ophthalmology is the only setting where anything can be attempted, and the window is minutes.
- If you are the injector: have hyaluronidase drawn and ready before every periocular procedure. Some emergency protocols recommend immediate high-dose injection into the area while awaiting emergency services - know your protocol before you need it.
Symptoms to treat as warnings: sudden blurring or loss of vision in one eye, eye pain, a severe headache beginning during or immediately after injection, or skin blanching and mottling around the injection site.
Of published filler-related visual loss cases that reported outcomes, reversible vision loss occurred in a small minority. The ophthalmic artery's anatomy makes this the highest-stakes injection site on the face.Based on literature review, PMC11826751
Reversal with Hyaluronidase: How It Works and What Can Go Wrong
Hyaluronidase is an enzyme that cleaves the bonds in hyaluronic acid, breaking down HA filler in the tissue. For the HA products used in tear trough treatment, it functions as a genuine reversal agent rather than a partial correction.
Speed and timing
Tightly cross-linked HA products begin softening within one to two hours of enzyme injection and break down substantially within 24 hours. Most enzymatic activity is complete within three to seven days. Practitioners should wait a minimum of two full weeks before re-injecting into a treated area - re-injecting while the enzyme is still active degrades new filler before it settles.
Published consensus guidelines specify dosing by product type and cross-linking density. The appropriate amount varies significantly between a lightly cross-linked filler and a highly cross-linked one. Dosing is not guesswork - if your injector cannot reference a specific guideline for the product being dissolved, ask about their approach.
Post-hyaluronidase syndrome: the reversal's own complication
Hyaluronidase does not distinguish between injected HA and the body's own naturally present hyaluronic acid in periorbital tissue. Used at too high a dose, it dissolves both. The result is new hollowness that was not present before treatment - the same tear trough depression that prompted filler in the first place, but now deeper than baseline.
Conservative staged dosing with a full two-week review before adding more enzyme avoids this in most cases. Patients should ask specifically about this risk before consenting to dissolution.
Who Should Never Get Tear Trough Filler - and What the Right Treatment Is
The most preventable adverse outcome in tear trough treatment is not a technique failure - it is the wrong patient getting the procedure at all. Filler corrects one specific finding: volume loss that creates a structural shadow. Two other causes of the tired under-eye appearance are routinely confused with this and do not respond to filler.
Orbital fat herniation
When fat pads behind the eye push forward through a weakening orbital septum, they create puffy bags below the lower lid that cast a shadow. Patients often believe they have a hollow needing filler. In reality, adding volume to this anatomy worsens the puffiness - filler adds to an already-bulging structure. The correct treatment for orbital fat herniation is surgical: fat repositioning or removal through lower blepharoplasty. Injecting into this presentation causes harm.
Pigmentation-based dark circles
Dark circles caused by melanin in the skin itself do not respond to filler. The color is in the dermis, not cast by a structural shadow. Adding volume underneath changes nothing. These circles need skin-targeted treatment: topical agents, chemical peels, or laser approaches, depending on the cause.
Poor candidates for tear trough filler include:
- Those whose darkness comes from fat pad herniation - soft puffiness that worsens when lying down or looking down
- Those with pigmentation-based dark circles where the skin itself is discolored rather than shadowed
- Those with very thin or translucent lower eyelid skin through which any filler immediately becomes visible
- Those with prior lower eyelid surgery that has changed the tissue planes
- Those with active skin infection, cold sore, or inflammation in the periocular area
- Those on anticoagulant medication that significantly raises bleeding risk, without medical clearance
The right question before any tear trough appointment is not 'how much filler do I need' but 'is filler the correct treatment for my specific anatomy.'
Frequently Asked Questions
How can I tell whether my dark circles are from volume loss or something else?
Look at the area under different lighting conditions. Volume-loss shadows look darker under directional light and lighter under flat, even light because the shadow changes with the angle. Pigmentation-based circles stay the same shade regardless of lighting direction. Fat herniation bags look puffier when you tilt your head forward or have been lying down for a while. A consultation that involves examining the area in different positions is more reliable than any at-home test.
If the Tyndall effect is not treated, does it get worse over time?
It does not typically worsen, but it does not improve either. The blue-gray tint persists as long as the filler remains at that depth. Some patients carry it for years without recognizing it as a treatable complication. Hyaluronidase resolves it reliably once the cause is correctly identified.
What should I do if a lump appears several months after my filler, with no other symptoms?
Book a review with your injector rather than waiting. A lump appearing long after treatment may indicate migration, a delayed nodule, or an immune-mediated reaction - each of which needs assessment to determine the right response. Tell your injector whether you have had a recent illness or vaccination, as this timing is clinically relevant and changes the approach.
Can choosing a more experienced injector eliminate the vascular occlusion risk?
Experience and anatomical knowledge reduce risk through better injection plane selection and technique, but do not reduce it to zero. The angular artery's exact position varies between individuals, and no injector can see the needle tip in real time. The more important factors are choosing a practitioner who understands the anatomy, keeps hyaluronidase immediately available, and knows how to recognize early warning signs - while accepting that the risk cannot be fully removed.
If I dissolve my filler, will I look worse than before I had it?
Not necessarily, but it is possible - particularly if high doses of hyaluronidase are used in a single session. The enzyme can dissolve the body's own natural HA alongside the injected product, creating hollowness that was not there before treatment. Conservative staged dosing with a two-week review interval avoids this in most cases. Before consenting to dissolution, ask your injector specifically how they approach dosing to protect against post-hyaluronidase volume loss.
Is there any filler product that is safer for tear troughs than others?
Softer, more hydrophilic HA products with lower cross-linking are generally preferred for the tear trough because they integrate with tissue more naturally and produce less visible lumpiness than firmer products designed for areas like the cheeks or jawline. No product eliminates the vascular risk, which is determined by injection technique and anatomy rather than product choice. Product selection affects the likelihood of Tyndall effect and overfill complications more than it affects arterial risk.